Skip to main content
. Author manuscript; available in PMC: 2015 Jun 18.
Published in final edited form as: Am J Transplant. 2015 Mar 12;15(5):1349–1359. doi: 10.1111/ajt.13133

Table 3.

Clinical features and clinical course for non-recurrent (19-26) patients.

Patient Recurrence Pre-Tx Ab Change in Ab levels post-Tx and/or RTX Clinical condition at last follow-up includingresponse to RTX, rejections, last biopsy findings, most recent proteinuria, ESRD and/or death
19 N NEG Neg PLA2R on biopsy, negative Abs post-Tx
20 N POS/3 NEG post-Tx Equivocal PLA2R on biopsy, negative Abs post-Tx
21 N NEG Neg PLA2R on biopsy, negative Abs post-Tx*
22 N NEG Neg PLA2R on biopsy, negative Abs post-Tx, 2 episodes ACR, progressed to ESRD¥
23 N POS/3 NEG post-Tx Equivocal PLA2R on biopsy, negative Abs post-Tx, proteinuria ~ 1000 mg/24hrs, on sirolimus
24 N NA ABO-incompatible Tx, Neg PLA2R on biopsy, negative Abs post-Tx, death 6 years post-Tx
25 N NEG Liver-kidney Tx, Neg PLA2R on biopsy, negative Ab by Western blot
26 N NEG Neg PLA2R on biopsy, negative Abs post-Tx
*

Native biopsy was negative for PLA2R antigen.

¥

Native biopsy was positive for PLA2R antigen. NEG = negative, POS = positive/semiquantitative Ab by Western blot, NA = not available. ACR = Acute cellular rejection.